Comprehensive Financial Consultants Institutional Inc. Buys New Stake in The Clorox Company (NYSE:CLX)

Comprehensive Financial Consultants Institutional Inc. purchased a new stake in The Clorox Company (NYSE:CLX) during the third quarter, according to its most recent filing with the SEC. The fund purchased 1,375 shares of the company’s stock, valued at approximately $224,000.

Several other hedge funds have also bought and sold shares of CLX. Insight Folios Inc lifted its position in shares of Clorox by 3.0% in the third quarter. Insight Folios Inc now owns 2,195 shares of the company’s stock worth $358,000 after buying an additional 63 shares in the last quarter. Fiduciary Group LLC boosted its position in shares of Clorox by 0.4% during the 2nd quarter. Fiduciary Group LLC now owns 19,050 shares of the company’s stock valued at $2,600,000 after acquiring an additional 72 shares during the last quarter. GHP Investment Advisors Inc. boosted its position in shares of Clorox by 2.0% during the 2nd quarter. GHP Investment Advisors Inc. now owns 3,634 shares of the company’s stock valued at $496,000 after acquiring an additional 72 shares during the last quarter. SPC Financial Inc. grew its holdings in shares of Clorox by 2.2% in the second quarter. SPC Financial Inc. now owns 3,485 shares of the company’s stock valued at $476,000 after purchasing an additional 75 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV increased its position in Clorox by 17.2% in the third quarter. Massmutual Trust Co. FSB ADV now owns 510 shares of the company’s stock worth $83,000 after purchasing an additional 75 shares during the last quarter. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Insider Buying and Selling

In related news, EVP Angela C. Hilt sold 1,733 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $165.52, for a total transaction of $286,846.16. Following the completion of the sale, the executive vice president now directly owns 13,471 shares in the company, valued at $2,229,719.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 0.57% of the stock is currently owned by insiders.

Clorox Stock Up 0.1 %

Shares of NYSE CLX opened at $162.85 on Friday. The Clorox Company has a 52-week low of $127.60 and a 52-week high of $169.09. The firm has a market capitalization of $20.16 billion, a price-to-earnings ratio of 56.74, a PEG ratio of 3.02 and a beta of 0.41. The stock has a 50 day moving average price of $161.89 and a 200 day moving average price of $146.58. The company has a debt-to-equity ratio of 11.08, a quick ratio of 0.62 and a current ratio of 1.00.

Clorox (NYSE:CLX) last issued its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.50. The business had revenue of $1.76 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.49 EPS. Sell-side analysts expect that The Clorox Company will post 6.81 earnings per share for the current year.

Clorox Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 7th. Investors of record on Wednesday, October 23rd were issued a dividend of $1.22 per share. This represents a $4.88 annualized dividend and a yield of 3.00%. The ex-dividend date of this dividend was Wednesday, October 23rd. Clorox’s payout ratio is 170.04%.

Analyst Ratings Changes

A number of research firms have recently weighed in on CLX. Barclays boosted their target price on shares of Clorox from $137.00 to $139.00 and gave the stock an “underweight” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft upped their price objective on Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Jefferies Financial Group upgraded Clorox from a “hold” rating to a “buy” rating and lifted their target price for the stock from $174.00 to $187.00 in a report on Tuesday, October 1st. TD Cowen upgraded Clorox from a “sell” rating to a “hold” rating and increased their price target for the company from $155.00 to $170.00 in a report on Wednesday. Finally, Evercore ISI dropped their price objective on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating for the company in a research note on Monday, October 14th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Clorox presently has an average rating of “Hold” and an average target price of $155.00.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.